KPTI
Karyopharm Therapeutics Inc.NASDAQHealthcare$5.89+7.30%ClosedMarket Cap: $50.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.39
P/S
0.37
EV/EBITDA
-2.89
DCF Value
$-69.54
FCF Yield
-139.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.9%
Operating Margin
-62.1%
Net Margin
-134.2%
ROE
77.9%
ROA
-180.8%
ROIC
-236.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $34.1M | 95.6% | $-17.8M | $-102.2M | $-5.69 | — |
| FY 2025 | $146.1M | 95.9% | $-90.7M | $-196.0M | $-17.93 | — |
| Q3 2025 | $44.0M | 95.2% | $-15.2M | $-33.1M | $-3.82 | — |
| Q2 2025 | $37.9M | 97.2% | $-24.4M | $-37.3M | $-4.32 | — |
| Q1 2025 | $30.0M | 95.7% | $-33.3M | $-23.5M | $-2.77 | — |
| Q4 2024 | $30.5M | 95.6% | $-31.3M | $-30.8M | $-3.67 | — |
| FY 2024 | $145.2M | 95.9% | $-119.4M | $-76.4M | $-9.41 | — |
| Q3 2024 | $38.8M | 96.6% | $-26.3M | $-32.1M | $-3.85 | — |
| Q2 2024 | $42.8M | 96.4% | $-28.1M | $23.8M | $-2.97 | — |
| Q1 2024 | $33.1M | 94.0% | $-33.8M | $-37.4M | $-4.85 | — |
| Q4 2023 | $33.7M | 95.4% | $-37.8M | $-41.8M | $-5.47 | — |
| FY 2023 | $146.0M | 96.6% | $-129.5M | $-143.1M | $-18.79 | — |